The Cochrane Collaboration Complementary Medicine Field is pleased to announce our 2014 bursary scheme made possible through funds from the US National Institutes of Health, National Center for Complementary and Alternative Medicine. The purpose of this bursary scheme is to ensure that reviews relevant to complementary and alternative medicine (CAM) are completed and published in the Cochrane Library.External link for more information: http://cam.cochrane.org/bursary-scheme Contributor's Information Contributor's name: Susan Wieland Email address: firstname.lastname@example.org
Are you a Cochrane author? Are you active on Twitter? We were very pleased to have Cochrane CEO Mark Wilson join us as guest host of the December edition of the #cochraneauthor Twitter chat. If you missed it, you can read the transcript here.Contributor's Information Contributor's name: Cochrane CEAD Email address: email@example.com
The National Health and Medical Research Council (NHMRC), Cochrane's principal funder in Australia, has announced its support of the AllTrials initiative. The NHMRC has published the following statement:
The National Health and Medical Research Council (NHMRC) is pleased to support the principles of the AllTrials statement.
The Cochrane Communications and External Affairs Department (CEAD) is pleased to announce that Sylvia De Haan MSc, MPH, Coordinator Cochrane Switzerland, Lausanne, will be Cochrane's new part-time WHO Co-ordinator, effective January 2015.External link for more information: http://www.cochrane.org/about-us/relations-world-health... Contributor's Information Contributor's name: Cochrane CEAD Email address: firstname.lastname@example.org
Only half of patients take their medications as prescribed: are there interventions that will help them?
Strictly Embargoed Until 00.01 Hours (GMT), Thursday, November 20, 2014
Evelyn Martinez (US): +1 201 748 6358
Jo Anthony (UK): +44 (0) 1865 310138 or +44 (0) 7990 031904
Three Cochrane Review Groups - Pain, Palliative and Supportive Care (PaPaS), Musculoskeletal (MSG) and Neuromuscular Diseases (NMD) - are planning to hold an hour-long Tweetchat on patient-preferred fibromyalgia outcomes on Tuesday 9th December, at 13:00 GMT, using the hashtag #CCFibro.
For more information, see below:
Objective: for Cochrane Review Groups to engage with relevant consumer and patient groups using simple questions to identify important outcomes in fibromyalgia, via Twitter.Contributor's Information Contributor's name: Anna Hobson Email address: email@example.com
The Canadian Cochrane Centre (CCC) is pleased to announce the winners of its 'What's your story?' competition, highlighting stories of how Cochrane evidence has made an impact on the lives of Canadians.External link for more information: http://ccnc.cochrane.org/winners-whats-your-story-compe... Contributor's Information Contributor's name: Lori Tarbett Email address: firstname.lastname@example.org
Post: Head of Learning and Support
Specifications: Full time, permanent
Salary: Dependent on skills and experience
Closing date for applications: 12 December 2014External link for more information: http://training.cochrane.org/ Contributor's Information Contributor's name: Rachael Wallwork Email address: email@example.com
A new survey about prioritising research questions in mild to moderate hearing loss has been launched by the James Lind Alliance (JLA), with the support of UK-based Cochrane contributors. The JLA has set up a Priority Setting Partnership (PSP) to identify unanswered questions for mild-moderate hearing loss; its causes, diagnosis, management and self-management.External link for more information: http://www.hearinglink.org/jla-psp/survey Contributor's Information Contributor's name: Sarah Chapman Email address: Sarah.Chapman@cochrane.nhs.uk
Cochrane Depression, Anxiety and Neurosis Group announces the establishment of a Suicide and Self-Harm Satellite
It is with great pleasure that the Cochrane Depression, Anxiety and Neurosis Group (CCDAN) announces the formation of a Suicide and Self-Harm satellite based in Swansea, Wales.External link for more information: http://ccdan.cochrane.org/ Contributor's Information Contributor's name: Jessica Sharp Email address: firstname.lastname@example.org
Strictly Embargoed Until 00.01 Hours (GMT), Thursday, November 6, 2014
[19.01 Hours US Eastern Time, Wednesday, November 5 /11.01 Hours Australian Eastern Daylight Time (AEDT), November 6]
Please take some time to fill out the evaluation forms for the 22nd Cochrane Colloquium using the link provided below.
If you were a day registrant, you can give your feedback just for that particular day.External link for more information: https://colloquium.cochrane.org/22nd-cochrane-colloquiu... Contributor's Information Contributor's name: Anna Joseph Email address: email@example.com
The first ever citation screening challenge is complete!
Starting at 15:00 GMT on Friday 31st October and running for 48 hours, around 75 EMBASE project screeners worked their way through 20,709 citations, in the process identifying 1713 RCTs. To put this into context, this work, completed in two days, is about the same amount of records as screeners typically review in two months.External link for more information: http://www.metaxis.com/EmbaseChallenge Contributor's Information Contributor's name: Anna Noel-Storr Email address: firstname.lastname@example.org
Strictly Embargoed Until 00.01 Hours (GMT), Thursday, October 30, 2014
[20.01 Hours US Eastern Time (EDT), October 29 /11.01 Hours Australian Eastern Daylight Time (AEDT), October 30]
It seems to me that what is missing is the views of parents and partners of patients who can give their take on what the patients are reporting. Only then will the true picture of the situation of people with psychosis be available, as patient views would be ratified - or contradicted - by those involved in their care long-term.
Our son started experimenting with cannabis when he was fourteen and we feel strongly that this contributed to his developing schizophrenia from about the age of seventeen. It became apparent during his prolonged stay in a psychiatric unit under a section that he was also treatment resistant. Only when he was treated with clozapine which had to be augmented did he begin to stabilise.
The doctor treating him felt that he, in his practice, was seeing more young men like this and he felt that the brain being bathed in these illicit drugs during adolescence was a contributory factor.
Our son managed to procure cannabis whilst in hospital under section and was cautioned and fined for this despite at the time not being deemed fit to make decisions. Fortunately he now no longer smokes cannabis but has to take medication and lives in supported accommodation. He is now 23 years old and is just beginning to have a life again.